Acute kidney injury (AKI) is a complication of
sepsis and leads to a high mortality rate. Human and animal studies suggest that
mitochondrial dysfunction plays an important role in
sepsis-induced multi-organ failure; however, the specific mitochondrial targets damaged during
sepsis remain elusive. We used a clinically relevant cecal
ligation and
puncture (CLP) murine model of
sepsis and assessed renal mitochondrial function using high-resolution respirometry, renal microcirculation using intravital microscopy, and renal function. CLP caused a time-dependent decrease in mitochondrial complex I and II/III respiration and reduced
ATP. By 4 h after CLP, activity of
manganese superoxide dismutase (MnSOD) was decreased by 50% and inhibition was sustained through 36 h. These events were associated with increased mitochondrial
superoxide generation. We then evaluated whether the mitochondria-targeted
antioxidant Mito-
TEMPO could reverse renal
mitochondrial dysfunction and attenuate
sepsis-induced AKI. Mito-
TEMPO (10 mg/kg) given at 6 h post-CLP decreased mitochondrial
superoxide levels, protected complex I and II/III respiration, and restored MnSOD activity by 18 h. Mito-
TEMPO also improved renal microcirculation and glomerular filtration rate. Importantly, even delayed
therapy with a single dose of Mito-
TEMPO significantly increased 96-h survival rate from 40% in untreated septic mice to 80%. Thus,
sepsis causes sustained inactivation of three mitochondrial targets that can lead to increased mitochondrial
superoxide. Importantly, even delayed
therapy with Mito-
TEMPO alleviated kidney injury, suggesting that it may be a promising approach to treat septic AKI.